Trial
NCT00276744
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI)
Condition
Pancreatic Cancer
Intervention
cetuximab
Why stopped
Because there was no longer an active laboratory component to this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-24